Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Amgen Inc. (AMGN)

NASDAQ: AMGN · Biotechnology · Thousand Oaks, CA

Our rating: Neutral

Neutral reaffirmed at $460.28, moderate conviction, November 5, 2026.

Breaks if: The Neutral call turns Cautious if revenue growth decelerates to below 5% year-over-year or the free cash flow margin falls below 18% (against the current ~22%) in any reported period — either signals the franchise is losing momentum at a multiple that cannot absorb it. It turns Positive if revenue growth sustains above 15% for two consecutive reported quarters, indicating the new-product cycle is running materially ahead of what the current price already reflects.

Key figures

Market value$235.6B
Revenue, last 12 months$38.9B
Net income, last 12 months$9.4B
Free cash flow, last 12 months$9.6B
Price to earnings25.1×
Free cash flow yield4.1%
Dividend yield2.9%
Operating margin32.4%
Return on equity78.4%
Beta to the S&P 5000.47
Volatility, annualized27.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$10.4B8.5%$7.08$3.7B
June 30, 2026$10.1B9.5%$4.37$3.5B
March 31, 2026$8.6B5.8%$3.34$1.5B
December 31, 2025$9.9B8.6%$2.46$961M
September 30, 2025$9.6B12.4%$5.93$4.2B
June 30, 2025$9.2B9.4%$2.65$1.9B
March 31, 2025$8.1B9.4%$3.20$980M
December 31, 2024$9.1B10.9%$1.16$4.4B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

17 ledger entries and 41 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.